Chinese Journal of Cancerindexed by SCI
《癌症》杂志
BMC

About the cover
About the cover

Jul. 2015; Volume 34 Issue 7


In July 2000, the US FDA approved tamoxifen to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Tamoxifen is the first medication to be approved for DCIS, which accounts for nearly 20 percent of all newly diagnosed breast cancer cases. From The Coming Cancer Breakthroughs.


Perspective
Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
Xiao Xu
[ Abstract  1392]  [ PDF Full-text  1638]   [ HTML Full-text  946]    Epub: 2015-7-8  doi: 10.1186/s40880-015-0029-3
Original Article
Insight into early-phase trials for lung cancer in the United States
Jin-Ji Yang and Yi-Long Wu
[ Abstract  957]  [ PDF Full-text  1126]   [ HTML Full-text  979]    Epub: 2015-7-11  doi: 10.1186/s40880-015-0027-5
Review
Predictive biomarkers in precision medicine and drug development against lung cancer
Bingliang Fang, Reza J Mehran, John V Heymach and Stephen G Swisher
[ Abstract  981]  [ PDF Full-text  1204]   [ HTML Full-text  952]    Epub: 2015-7-3  doi: 10.1186/s40880-015-0028-4
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Fei Zhou and Cai-Cun Zhou
[ Abstract  917]  [ PDF Full-text  1046]   [ HTML Full-text  958]    Epub: 2015-7-18  doi: 10.1186/s40880-015-0036-4
Global efforts in conquering lung cancer in China
Li Yan and Li Xu
[ Abstract  883]  [ PDF Full-text  986]   [ HTML Full-text  855]    Epub: 2015-7-28  doi: 10.1186/s40880-015-0034-6
Letter to the Editor
Early-Phase Oncology Research Training (EFFORT) program: a Hengrui-USCACA joint scholarship
Li Yan and Li Xu
[ Abstract  1308]  [ PDF Full-text  1154]   [ HTML Full-text  1058]    Epub: 2015-7-8  doi: 10.1186/s40880-015-0035-5




CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CJC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China